07:35 AM EDT, 05/21/2025 (MT Newswires) -- ME Therapeutics Holdings ( METXF ) on Wednesday said it is receiving advisory services and up to $140,000 in funding from the federal government.

Funding will support the research and development of the company's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease.

ME's lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already shown encouraging anti-cancer activity in a mouse model of colorectal cancer, a statement noted. ME Therapeutics ( METXF ) is also investigating modifying its mRNA candidates for increased efficacy and safety in specific tissues.